AMENDMENT

In the Claims:

Please amend claims 2-8, 11-14 and 27 as follows:

2. (Amended) The method according to claim 1, wherein the construct is delivered directly into a subject.

3. (Amended) The method according to claim 2, wherein the construct in delivered by injection, transdermal particle delivery, inhalation, topically, intranasally or transmucosally.

E'

4. (Amended) The method according to claim 3, wherein the construct is delivered by needleless injection.

5. (Twice Amended) The method according to claim 1, wherein the construct is delivered *ex vivo* into cells taken from a subject.

6. (Twice Amended) The method according to claim 5, wherein the subject is a human.

7. (Twice Amended) The method according to claim 1, wherein the antigen is a full length protein.

8. (Amended) The method according to claim 7, wherein the antigen is an antigen of a viral, bacterial, parasite or fungal pathogen.

11. (Amended) The method according to claim 1, wherein the nucleic acid construct is coated onto carrier particles.

12. (Amended) The method according to claim 1, wherein the nucleic acid construct is a DNA construct.

B2

13. (Amended) The method according to claim 1, wherein the minimal promoter sequence consists essentially of a human cytomegalovirus (hCMV) immediate early promoter sequence, a pseudorabies virus (PRV) early promoter region, a simian cytomegalovirus (sCMV) immediate early promoter sequence or a functional variant thereof.

14. (Amended) The method according to claim 13, wherein the minimal promoter sequence consists essentially of the sequence spanning positions 0 to -118 of the hCMV immediate early promoter region or a functional variant of the said spanning sequence.

B3

27. (Amended) The vector according to claim 26 which is a plasmid.